Challenges and solutions in bioanalysis for oligonucleotide drugs
Decode the challenges, unlock the solutions: bioanalysis for oligonucleotide drugs
The development of oligonucleotide-based therapeutics has recently attracted extensive attention due to their eminent potential. Oligonucleotide therapies have many advantages, including ease of design, a wide range of targets and high specificity. However, the chemical characteristics of oligonucleotides pose a significant challenge for bioanalysis. In addition, the immunogenicity and immunotoxicity potential of oligonucleotides are of concern in preclinical and clinical trials. To better facilitate oligonucleotide drug development, we share some bioanalytical strategies and case studies regarding the mitigation of these challenges.
What will you learn?
Strategies and practical tips for bioanalysis for oligonucleotide drugs
Who may this interest?
- Scientists from industry working with oligonucleotide drugs
- Scientists from academia working with oligonucleotide drugs
Speaker
Jinpeng Li, Ph.D.
Director
WuXi AppTec (Jiangsu, China)
Jinpeng Li currently serves as the Director of the Immunology Lab in the Bioanalysis Department of WuXi AppTec, focusing on leveraging bioanalytical technologies to aid drug research and development. Dr Li received a PhD in Genetics and Environmental Toxicology from Michigan State University (MI, USA). Before joining WuXi AppTec, he worked at Dow Chemical (MI, USA) and served as an Assistant Professor at Michigan State University, with his primary research focus being immunotoxicology. Dr Li has authored 16 peer-reviewed publications and was awarded the Diplomate of the American Board of Toxicology (DABT) credential.
This webinar was recorded on Monday 06 June 2024
In association with
